Languages
  • Français
  • English
  • Leadership
  • Our Pipeline
    • Viaskin™ Peanut
    • Viaskin™ Milk
    • Viaskin™ Egg
    • Expanded Access Program
    • Scientific Publications & Presentations
  • Viaskin® Platform
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Financial Information
      • SEC Filings
      • AMF Regulated Information
      • Annual Reports & General Meetings
    • Stock Information
    • Investor FAQs
    • Corporate Governance
      • Board of Directors
      • Audit Committee
      • Compensation Committee
      • Nominating Committee
  • Careers
  • Contact Us
The epicutaneous immunotherapy company
  • Leadership
  • Our Pipeline
    • Viaskin™ Peanut
    • Viaskin™ Milk
    • Viaskin™ Egg
    • Expanded Access Program
    • Scientific Publications & Presentations
  • Viaskin® Platform
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Financial Information
      • SEC Filings
      • AMF Regulated Information
      • Annual Reports & General Meetings
    • Stock Information
    • Investor FAQs
    • Corporate Governance
      • Board of Directors
      • Audit Committee
      • Compensation Committee
      • Nominating Committee
  • Careers
  • Contact Us

2021 Q1 Financial Results

Home » Events » 2021 Q1 Financial Results
Loading Events

« All Events

2021 Q1 Financial Results

May 3

  • « 2020 Annual Results
  • 2021 Annual General Meeting »
+ Google Calendar+ iCal Export

Details

Date:
May 3
  • « 2020 Annual Results
  • 2021 Annual General Meeting »
  • About Us
  • Leadership
  • Our Pipeline
  • Viaskin® Platform
  • Investors & Media
  • Contact Us
Follow Us
© 2018 DBV Technologies. All rights reserved.
DBV Technologies therapies are investigational and not FDA approved.
  • Terms of Use
  • Your California Privacy Rights
2020 Annual Results
2021 Annual General Meeting